Pliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical study of bexotegrast in patients with idiopathic pulmonary fibrosis, or ...

Pliant Therapeutics halted its Phase 2b trial for bexotegrast in IPF, raising concerns about future prospects. Needham downgraded Pliant to Hold from Buy, citing a lack of near-term catalysts and ...

Pliant is committed to the development of its other clinical and pipeline assets including PLN-101095 in oncology. The Company is currently enrolling the fourth of five planned dose cohorts in a ...